Rituxan

Latest articles

3d
Channel NewsAsia
Biosimilar cancer drug threat closing in for Rocheof the second so-called cancer biosimilar in Europe this year, following the la
Channel NewsAsia / Posted 3 days ago
of the second so-called cancer biosimilar in Europe this year, following the launch six months ago of copies of MabThera/Rituxan for blood cancers. Across the Atlantic, U.S. regulators have approved a biosimilar version of Avastin for a range of... Read more
10d
Channel NewsAsia
Roche shares hit by trial flops, fears over biosimilar defensecheaper biosimilar copies of its biggest sellers - the US$20 billion-a-year tri
Channel NewsAsia / Posted 10 days ago
cheaper biosimilar copies of its biggest sellers - the US$20 billion-a-year trio of cancer drugs Herceptin, Avastin and Rituxan. But the recent flops, coupled with disappointing results this year on its immunotherapy Tecentriq and its... Read more
12d
Channel NewsAsia
Roche eye drug fails late-stage trial in blow to pipelineimpact of cheaper copies of its biggest sellers - the US$20-billion-per-year tr
Channel NewsAsia / Posted 12 days ago
impact of cheaper copies of its biggest sellers - the US$20-billion-per-year trio of cancer drugs Herceptin, Avastin and Rituxan - that are starting to hit the market. Its failure in tests is the latest in a string of disappointing trial results... Read more
24d
Business Wire
FDA Grants Priority Review for Genentech’s Gazyva in Previously Untreated Follicular Lymphomathe first Phase III study in previously untreated follicular lymphoma to show s
Business Wire / Posted 24 days ago
the first Phase III study in previously untreated follicular lymphoma to show superior progression-free survival (PFS) over Rituxan® (rituximab)-based treatment, the current standard of care. Adverse events (AEs) with either Gazyva or Rituxan were... Read more
m
Morningstar
Promise in New Cancer Treatments, for Patients and Investorscommunity that the biosimilars will take a lot of market share from Roche’s old
Morningstar / Posted 1 months ago
community that the biosimilars will take a lot of market share from Roche’s older biologics, drugs like Herceptin and Rituxan. We also think the biosimilars are going to take some market share. But we think people are underappreciating Roche’s... Read more

In this news